Clinical reference Biomarker Directory
Back to directory

PAPPA

Established

PAPP-A is a first-trimester screening marker for chromosomal abnormalities, also linked to later placental complications.

Also known as PAPP-A pregnancy-associated plasma protein A
In plain language

PAPP-A is a pregnancy protein measured early on to help screen for Down syndrome, usually combined with an ultrasound measurement and another hormone. A low level, even if the chromosome screening looks fine, can also be a clue that the placenta may need closer watching later in pregnancy.

Biomarker & context

Pregnancy-associated plasma protein A (PAPP-A) is produced by the placenta; low first-trimester levels are used in combination with other markers to screen for fetal chromosomal abnormalities, particularly Down syndrome.

What it indicates

Low PAPP-A, combined with free beta-hCG and nuchal translucency ultrasound measurement, contributes to first-trimester Down syndrome screening; low PAPP-A also independently associates with later placental complications (preeclampsia, fetal growth restriction), an underappreciated secondary signal beyond its screening role.

Diagnosis & clinical testing

Measured via maternal serum immunoassay during the first trimester (typically 10-13 weeks), combined into a composite risk score with nuchal translucency and beta-hCG; abnormal results prompt discussion of further testing (NIPT, diagnostic amniocentesis/CVS).

Guiding treatment

Low PAPP-A findings, even when chromosomal screening is otherwise reassuring, may prompt closer monitoring for placental-mediated pregnancy complications later in pregnancy, given the marker's broader association with placental function.

Clinical significance

Low levels carry secondary prognostic value for placental-mediated pregnancy complications beyond chromosomal screening.

References
  1. General obstetric reference literature on first-trimester combined screening and PAPP-A's association with placental complications.